Abstract 3347: Sirolimus Eluting Stents In Single Vessel Versus Multi-vessel Percutaneous Coronary Intervention: Results From The Matrix Registry
Background The efficacy of sirolimus eluting stents (SES) to reduce in-stent restenosis compared to bare metal stents has been studied in single coronary vessels. However, the long-term efficacy and safety of SES implantation in multiple coronary vessels has not been well studied. We compared the efficacy and safety of SES implanted in single vessel versus multi-vessel PCI.
Methods The MATRIX registry prospectively evaluates the efficacy and safety of SES in a “real world” population. In this registry, SES was implanted in single vessel PCI in 1103 patients and in multi-vessel PCI in 321 patients. Dual anti-platelet therapy with aspirin and clopidogrel was recommended for at least one year. All clinical events are source-documented and adjudicated by an independent committee.
Results The multi-vessel PCI group had more patients with diabetes (38.4% vs. 32.4%, p=0.04), but less patients with prior PCI (37.7% vs. 46.6%, p=0.006) and prior CABG (17% vs. 22.3%, p=0.04). The mean number of stents implanted was 1.7 ± 0.9 vs. 3.1 ± 1.1 with procedural success of 96.7% vs. 95.6% in single and multi-vessel PCI groups respectively. The two-year clinical outcomes are shown in the table⇓.
Conclusions We documented no significant differences in single vs. multi-vessel PCI with sirolimus DES. Therefore, with appropriate patient selection and PCI technique, the treatment with multi-vessel PCI appears to be as safe and effective as single vessel PCI.